Atogepant (Qulipta) for Migraine Prevention

Date: November 1, 2021 Issue #:  1636Summary:  Atogepant (Qulipta– Abbvie), an oral small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist ( " gepant " ), has been approved by the FDA for prevention of episodic migraine in adults. It is the second oral CGRP receptor antagonist to be approved in the US for this indication; the first was rimegepant(Nurtec ODT), which is also approved for acute treatment of migraine. Parenteral CGRP monoclonal antibodies are approved for prevention of migraine (see Table 3).
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Tags: Aimovig Ajovy Amerge Atacand atogepant Beta blockers Botox Candesartan Cymbalta Depakote Divalproex sodium Duloxetine Effexor Emgality Epival eptinezumab erenumab fremanezumab Frova Frovatriptan galcanezumab Lopre Source Type: research